Date Title Description PDF
27 Feb 2024 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
08 Nov 2023 On P&L The Company releases the first nine months 2023 financial results presentation Download
08 Nov 2023 On P&L The Company releases the press release related to the first nine months of 2023 financial results Download
26 Jul 2023 On P&L The Company releases the press release related to the first half 2023 financial results Download
26 Jul 2023 On P&L The Company releases the first half 2023 financial results presentation Download

Pages

Date Title Description PDF
12 Mar 2024 On business and financial situation ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies Download
08 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 March and 7 March 2024 Download
07 Mar 2024 On corporate transactions ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives  Download
01 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 23 February and 29 February 2024 Download
27 Feb 2024 Annual Corporate Governance Report ROVI releases the 2023 Annual Corporate Governance Report Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages